mosunetuzumab follicular
Selected indexed studies
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (Lancet Oncol, 2022) [PMID:35803286]
- Mosunetuzumab for the treatment of follicular lymphoma. (Expert Opin Biol Ther, 2024) [PMID:39259182]
- Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. (Blood, 2025) [PMID:39447094]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. (2025) pubmed
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (2022) pubmed
- Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. (2025) pubmed
- Mosunetuzumab for the treatment of follicular lymphoma. (2024) pubmed
- Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. (2023) pubmed
- Bispecific antibodies in follicular lymphoma. (2025) pubmed
- Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. (2025) pubmed
- PMID:40138506 (2023) pubmed
- Mosunetuzumab (Lunsumio) for follicular lymphoma. (2023) pubmed
- Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. (2025) pubmed